Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,643 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP. Hayashi M, et al. Among authors: ishikawa t. Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596. Anticancer Res. 2019. PMID: 31366522 Clinical Trial.
[Advances in breast cancer chemotherapy].
Ishikawa T, Shimizu S, Momiyama N, Ichikawa Y, Shimada H. Ishikawa T, et al. Nihon Rinsho. 2006 Mar;64(3):529-35. Nihon Rinsho. 2006. PMID: 16529045 Review. Japanese.
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.
Ishikawa T, Shimizu S, Katayama K, Chishima T, Hamaguchi Y, Doi T, Tanabe M, Kasahara A, Yamaguchi N, Narui K, Ohta I, Matsumoto C, Shimizu D, Kito A, Suda T, Inaba M, Asaga T, Momiyama N, Ichikawa Y, Yoshimoto M, Morita S, Shimada H. Ishikawa T, et al. Anticancer Res. 2009 May;29(5):1515-20. Anticancer Res. 2009. PMID: 19443359 Free article.
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S. Takahashi S, et al. Among authors: ishikawa t. Breast Cancer Res Treat. 2012 Jun;133(2):685-93. doi: 10.1007/s10549-012-1973-0. Epub 2012 Feb 4. Breast Cancer Res Treat. 2012. PMID: 22307266 Clinical Trial.
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Hasegawa Y, Tanino H, Horiguchi J, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Akazawa K, Kohno N; JONIE Study Group. Hasegawa Y, et al. Among authors: ishikawa t. PLoS One. 2015 Dec 3;10(12):e0143643. doi: 10.1371/journal.pone.0143643. eCollection 2015. PLoS One. 2015. PMID: 26633806 Free PMC article. Clinical Trial.
Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
Kida K, Ishikawa T, Yamada A, Shimada K, Narui K, Sugae S, Shimizu D, Tanabe M, Sasaki T, Ichikawa Y, Endo I. Kida K, et al. Among authors: ishikawa t. Breast Cancer Res Treat. 2016 Apr;156(2):261-9. doi: 10.1007/s10549-016-3738-7. Epub 2016 Mar 14. Breast Cancer Res Treat. 2016. PMID: 26975188
7,643 results